EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Effectiveness of Electronic Quality Improvement Activities to Reduce Cardiovascular Disease Risk in People With Chronic Kidney Disease in General Practice: Cluster Randomized Trial With Active Control

Jo-Anne Manski-Nankervis iD, Barbara Hunter iD, Natalie Lumsden iD, Adrian Laughlin iD, Rita McMorrow iD, Douglas Boyle iD, Patty Chondros iD, Shilpanjali Jesudason iD, Jan Radford iD, Megan Prictor iD, Jon Emery iD, Paul Amores iD und 2 weitere

JMIR Formative Research · 2025

DOI: 10.2196/54147 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JMIR Formative Research, 2025. Verfasst von Jo-Anne Manski-Nankervis und 13 weiteren Autor:innen. Beteiligte Einrichtung: Primary Care and Family Medicine, Lee Kong Chian School of Medicine, Singapore, Singapore. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Quality Improvement, Cardiovascular Diseases, General Practice. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Future Health Today (FHT) is a program integrated with electronic medical record (EMR) systems in general practice and comprises (1) a practice dashboard to identify people at risk of, or with, chronic disease who may benefit from intervention; (2) active clinical decision support (CDS) at the point of care; and (3) quality improvement activities. One module within FHT aims to facilitate cardiovascular disease (CVD) risk reduction in people with chronic kidney disease (CKD) through the recommendation of angiotensin-converting enzyme inhibitor inhibitors (ACEI), angiotensin receptor blockers (ARB), or statins according to Australian guidelines (defined as appropriate pharmacological therapy).

Objective

This study aimed to determine if the FHT program increases the proportion of general practice patients with CKD receiving appropriate pharmacological therapy (statins alone, ACEI or ARB alone, or both) to reduce CVD risk at 12 months postrandomization compared with active control (primary outcome).

Methods

General practices recruited through practice-based research networks in Victoria and Tasmania were randomly allocated 1:1 to the FHT CKD module or active control. The intervention was delivered to practices between October 4, 2021, and September 30, 2022. Data extracted from EMRs for eligible patients identified at baseline were used to evaluate the trial outcomes at the completion of the intervention period. The primary analysis used an intention-to-treat approach. The intervention effect for the primary outcome was estimated with a marginal logistic model using generalized estimating equations with robust SE.

Results

Overall, of the 734 eligible patients from 19 intervention practices and 715 from 21 control practices, 82 (11.2%) and 70 (9.8%), respectively, had received appropriate pharmacological therapy (statins alone, ACEI or ARB alone, or both) at 12 months postintervention to reduce CVD risk, with an estimated between-trial group difference (Diff) of 2.0% (95% CI –1.6% to 5.7%) and odds ratio of 1.24 (95% CI 0.85 to 1.81; P=.26). Of the 470 intervention patients and 425 control patients that received a recommendation for statins, 61 (13%) and 38 (9%) were prescribed statins at follow-up (Diff 4.3%, 95% CI 0 to 8.6%; odds ratio 1.55, 95% CI 1.02 to 2.35; P=.04). There was no statistical evidence to support between-group differences in other secondary outcomes and general practice health care use.

Conclusions

FHT harnesses the data stored within EMRs to translate guidelines into practice through quality improvement activities and active clinical decision support. In this instance, it did not result in a difference in prescribing or clinical outcomes except for small changes in statin prescribing. This may relate to COVID-19–related disruptions, technical implementation challenges, and recruiting higher performing practices to the trial. A separate process evaluation will further explore factors impacting implementation and engagement with FHT. Trial Registration ACTRN12620000993998; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380119

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal Insufficiency, ChronicQuality ImprovementCardiovascular DiseasesGeneral PracticeElectronic Health RecordsHumansFemaleMaleMiddle AgedAgedAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsHydroxymethylglutaryl-CoA Reductase InhibitorsTasmaniaVictoriaDecision Support Systems, ClinicalAdult

Stichwörter der Autor:innen

cardiovascularcardiovascular diseasechronic kidney diseaseclinical decisionclinical decision supportdecision supportelectronic medical recordgeneral practicekidneykidney diseaselogistic modelmedical recordspharmacologicalpharmacological therapyprimary care

Substanzen

Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsHydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Primary Care and Family Medicine, Lee Kong Chian School of Medicine, Singapore, Singapore.
  • Centre for Research Excellence in Interactive Digital Technology to Transform Australia's Chronic Disease Outcomes, Prahan, Australia.
  • Department of General Practice and Primary Care, University of Melbourne, Melbourne, Australia.
  • Western Health Chronic Disease Alliance, Western Health, Sunshine, Australia.
  • Department of General Practice, University College Cork, Cork, Ireland.
  • Central Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, University of Adelaide, Adelaide, Australia.

ORCID-Profile: Jo-Anne Manski-Nankervis, Barbara Hunter, Natalie Lumsden, Adrian Laughlin, Rita McMorrow, Douglas Boyle, Patty Chondros, Shilpanjali Jesudason, Jan Radford, Megan Prictor, Jon Emery, Paul Amores, An Tran-Duy, Craig Nelson

Förderung

  • Cancer Research UK

Zitieren

APA

Manski-Nankervis, J. A., Hunter, B., Lumsden, N., Laughlin, A., McMorrow, R., Boyle, D., Chondros, P., Jesudason, S., Radford, J., Prictor, M., Emery, J., Amores, P., Tran-Duy, A., & Nelson, C. (2025). Effectiveness of Electronic Quality Improvement Activities to Reduce Cardiovascular Disease Risk in People With Chronic Kidney Disease in General Practice: Cluster Randomized Trial With Active Control. JMIR Formative Research. https://doi.org/10.2196/54147

Vancouver

Manski-Nankervis JA, Hunter B, Lumsden N, Laughlin A, McMorrow R, Boyle D, et al. Effectiveness of Electronic Quality Improvement Activities to Reduce Cardiovascular Disease Risk in People With Chronic Kidney Disease in General Practice: Cluster Randomized Trial With Active Control. JMIR Formative Research. 2025. doi:10.2196/54147

BibTeX
@article{ManskiNankervis2025,
  author = {Manski-Nankervis, Jo-Anne and Hunter, Barbara and Lumsden, Natalie and Laughlin, Adrian and McMorrow, Rita and Boyle, Douglas and Chondros, Patty and Jesudason, Shilpanjali and Radford, Jan and Prictor, Megan and Emery, Jon and Amores, Paul and Tran-Duy, An and Nelson, Craig},
  title = {Effectiveness of Electronic Quality Improvement Activities to Reduce Cardiovascular Disease Risk in People With Chronic Kidney Disease in General Practice: Cluster Randomized Trial With Active Control},
  journal = {JMIR Formative Research},
  year = {2025},
  doi = {10.2196/54147}
}
Kostenlos starten →